Answers are grounded in this paper and cite their sources.
Experimental analysis showed metabolic changes in sarcospheres from patients sensitive to romidepsin, suggesting new treatment avenues.
Sarcospheres from a subset of patients are sensitive to romidepsin. Metabolic activity of sarcospheres from 18 human (A) and 10 canine (B) patients was measured after exposure for 48 hours to the indicated concentrations of romidepsin. Black curves represent sensitive subset of patients with ED₅₀s <70 nmol/L. Gray curves represent resistant subset, defined as ED₅₀ >1,000 nmol/L. Each curve represents the mean of at least n = 3 independent experiments with sarcospheres from an individual patient sample. Each experiment included six sarcospheres at each of the indicated doses. Asterisks (*) indicate dose groups (100 and 1,000 nmol/L) that are significantly different (P < 0.05) from the vehicle-treated group for all sensitive samples based on one-way ANOVA with Dunnett multiple comparisons tests. C, Diameters of human patient–derived sarcospheres were measured every 2 hours during exposure to the indicated concentrations of romidepsin or vehicle by the Incucyte S3 Live Cell Analysis System (Sartorius). Each symbol represents mean ± SEM of N = 6 patients (two romidepsin sensitive and four romidepsin resistant). Sarcospheres from each patient were analyzed in 1–3 independent experiments. Each experiment included 3–6 sarcospheres per dose group. D, Representative images of romidepsin-sensitive sarcospheres from experiments depicted in C. Yellow size bars in lower left of images show 600 mm. Time stamp is shown in lower right of each image. E, Representative images from romidepsin-resistant patients from experiments depicted in C. Yellow size bars in lower left of images show 800 mm. Time stamp is shown in lower right of each image.
No takes yet. Share an insight, caveat, or question.
Seiden et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: